Bronchospasm induced by bevacizumab

Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma...

Full description

Saved in:
Bibliographic Details
Published in:Respirology case reports 2013-09, Vol.1 (1), p.14-16
Main Authors: Taniguchi, Hirokazu, Tsuchida, Tomoko, Nakamura, Yoichi, Motoshima, Kohei, Mizoguchi, Kosuke, Kohno, Shigeru
Format: Article
Language:English
Subjects:
Asthma
Bronchodilators
Cancer therapies
Case reports
Chemotherapy
Dyspnea
Hypoxia
Immunoglobulins
Immunotherapy
Lung cancer
Metastasis
Monoclonal antibodies
Outpatient care facilities
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 16
container_issue 1
container_start_page 14
container_title Respirology case reports
container_volume 1
creator Taniguchi, Hirokazu
Tsuchida, Tomoko
Nakamura, Yoichi
Motoshima, Kohei
Mizoguchi, Kosuke
Kohno, Shigeru
description Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow‐volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.
doi_str_mv 10.1002/rcr2.10
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2290621347</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2290621347</sourcerecordid><originalsourceid>FETCH-proquest_journals_22906213473</originalsourceid><addsrcrecordid>eNpjYOA3NNAzNDAw0i9KLjICspgYOI0MTA11jY0tDDgYeIuLswwMDAwNgUKGhpwMyk5F-XnJGfnFBYnFuQqZeSmlyakpCkmVCkmpZYnJmVWluYlJPAysaYk5xam8UJqbQdnNNcTZQ7egKL-wNLW4JD4rv7QoDygVb2RkaWBmZGhsYm5MnCoA_34yAA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2290621347</pqid></control><display><type>article</type><title>Bronchospasm induced by bevacizumab</title><source>Wiley-Blackwell Open Access Collection</source><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>Taniguchi, Hirokazu ; Tsuchida, Tomoko ; Nakamura, Yoichi ; Motoshima, Kohei ; Mizoguchi, Kosuke ; Kohno, Shigeru</creator><creatorcontrib>Taniguchi, Hirokazu ; Tsuchida, Tomoko ; Nakamura, Yoichi ; Motoshima, Kohei ; Mizoguchi, Kosuke ; Kohno, Shigeru</creatorcontrib><description>Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow‐volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.</description><identifier>EISSN: 2051-3380</identifier><identifier>DOI: 10.1002/rcr2.10</identifier><language>eng</language><publisher>Hoboken: John Wiley &amp; Sons, Inc</publisher><subject>Asthma ; Bronchodilators ; Cancer therapies ; Case reports ; Chemotherapy ; Dyspnea ; Hypoxia ; Immunoglobulins ; Immunotherapy ; Lung cancer ; Metastasis ; Monoclonal antibodies ; Outpatient care facilities ; Targeted cancer therapy</subject><ispartof>Respirology case reports, 2013-09, Vol.1 (1), p.14-16</ispartof><rights>2013. This work is published under http://creativecommons.org/licenses/by-nc-nd/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2290621347/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2290621347?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Tsuchida, Tomoko</creatorcontrib><creatorcontrib>Nakamura, Yoichi</creatorcontrib><creatorcontrib>Motoshima, Kohei</creatorcontrib><creatorcontrib>Mizoguchi, Kosuke</creatorcontrib><creatorcontrib>Kohno, Shigeru</creatorcontrib><title>Bronchospasm induced by bevacizumab</title><title>Respirology case reports</title><description>Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow‐volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.</description><subject>Asthma</subject><subject>Bronchodilators</subject><subject>Cancer therapies</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Dyspnea</subject><subject>Hypoxia</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Outpatient care facilities</subject><subject>Targeted cancer therapy</subject><issn>2051-3380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpjYOA3NNAzNDAw0i9KLjICspgYOI0MTA11jY0tDDgYeIuLswwMDAwNgUKGhpwMyk5F-XnJGfnFBYnFuQqZeSmlyakpCkmVCkmpZYnJmVWluYlJPAysaYk5xam8UJqbQdnNNcTZQ7egKL-wNLW4JD4rv7QoDygVb2RkaWBmZGhsYm5MnCoA_34yAA</recordid><startdate>20130901</startdate><enddate>20130901</enddate><creator>Taniguchi, Hirokazu</creator><creator>Tsuchida, Tomoko</creator><creator>Nakamura, Yoichi</creator><creator>Motoshima, Kohei</creator><creator>Mizoguchi, Kosuke</creator><creator>Kohno, Shigeru</creator><general>John Wiley &amp; Sons, Inc</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20130901</creationdate><title>Bronchospasm induced by bevacizumab</title><author>Taniguchi, Hirokazu ; Tsuchida, Tomoko ; Nakamura, Yoichi ; Motoshima, Kohei ; Mizoguchi, Kosuke ; Kohno, Shigeru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_22906213473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Asthma</topic><topic>Bronchodilators</topic><topic>Cancer therapies</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Dyspnea</topic><topic>Hypoxia</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Outpatient care facilities</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Taniguchi, Hirokazu</creatorcontrib><creatorcontrib>Tsuchida, Tomoko</creatorcontrib><creatorcontrib>Nakamura, Yoichi</creatorcontrib><creatorcontrib>Motoshima, Kohei</creatorcontrib><creatorcontrib>Mizoguchi, Kosuke</creatorcontrib><creatorcontrib>Kohno, Shigeru</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Respirology case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Taniguchi, Hirokazu</au><au>Tsuchida, Tomoko</au><au>Nakamura, Yoichi</au><au>Motoshima, Kohei</au><au>Mizoguchi, Kosuke</au><au>Kohno, Shigeru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bronchospasm induced by bevacizumab</atitle><jtitle>Respirology case reports</jtitle><date>2013-09-01</date><risdate>2013</risdate><volume>1</volume><issue>1</issue><spage>14</spage><epage>16</epage><pages>14-16</pages><eissn>2051-3380</eissn><abstract>Bevacizumab has a lower risk of treatment‐related infusion reactions than other humanized monoclonal antibodies, and bronchospasm induced by bevacizumab has not been reported. We administered bevacizumab 15 mg/kg over 90 min infusion to a 34 year‐old man with lung adenocarcinoma and childhood asthma. Then, grade 3 hypoxia developed and improved spontaneously. This reversible obstructive lung disorder was confirmed using a flow‐volume loop, and the patient was diagnosed as having a bronchospasm due to infusion reaction of bevacizumab. This bronchospasm was easily manageable and preventable using an oral bronchodilator and an inhalant combination product, and the patient continued with bevacizumab therapy until the disease progression.</abstract><cop>Hoboken</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/rcr2.10</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2051-3380
ispartof Respirology case reports, 2013-09, Vol.1 (1), p.14-16
issn 2051-3380
language eng
recordid cdi_proquest_journals_2290621347
source Wiley-Blackwell Open Access Collection; Open Access: PubMed Central; ProQuest - Publicly Available Content Database
subjects Asthma
Bronchodilators
Cancer therapies
Case reports
Chemotherapy
Dyspnea
Hypoxia
Immunoglobulins
Immunotherapy
Lung cancer
Metastasis
Monoclonal antibodies
Outpatient care facilities
Targeted cancer therapy
title Bronchospasm induced by bevacizumab
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A34%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bronchospasm%20induced%20by%20bevacizumab&rft.jtitle=Respirology%20case%20reports&rft.au=Taniguchi,%20Hirokazu&rft.date=2013-09-01&rft.volume=1&rft.issue=1&rft.spage=14&rft.epage=16&rft.pages=14-16&rft.eissn=2051-3380&rft_id=info:doi/10.1002/rcr2.10&rft_dat=%3Cproquest%3E2290621347%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_22906213473%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2290621347&rft_id=info:pmid/&rfr_iscdi=true